<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002392</url>
  </required_header>
  <id_info>
    <org_study_id>279A</org_study_id>
    <nct_id>NCT00002392</nct_id>
  </id_info>
  <brief_title>A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART</brief_title>
  <official_title>A Study to Investigate the Potential of Thalidomide Treatment to Enhance Immune Responses in HIV-Infected Individuals Who Are Receiving Highly Active Antiretroviral Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent&#xD;
      pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients;&#xD;
      particularly, on markers of immune activation and parameters of specific, anti-HIV cellular&#xD;
      immunity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive oral thalidomide in a blinded, placebo-controlled study. [AS PER AMENDMENT&#xD;
      11/25/98: This is a double-blind, placebo-controlled trial in which thalidomide or placebo is&#xD;
      administered for 21 days. After the first week of therapy, patients receive immunizations&#xD;
      with keyhole limpet hemocyanin and polyvalent pneumococcal vaccine. Study therapy is stopped&#xD;
      for 2 weeks after the immunizations. Following the immunizations, detailed evaluations of the&#xD;
      immune responses to the vaccines are conducted over the next 8 weeks.]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4+ cell count between 300 and 500 cells/mm3.&#xD;
&#xD;
          -  HIV-1 RNA &lt; 500 by the branched-chain DNA assay (bDNA assay, Chiron) within 21 days of&#xD;
             study entry [AS PER AMENDMENT 11/25/98:&#xD;
&#xD;
          -  Undetectable-plasma HIV titers (as defined by the FDA) by the branched-chain DNA&#xD;
             test].&#xD;
&#xD;
          -  Established B cell lines [deleted AS PER AMENDMENT 11/25/98].&#xD;
&#xD;
          -  Response to at least one recall antigen in an in vitro assay of lymphocyte&#xD;
             proliferative responses.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months [deleted AS PER AMENDMENT 11/25/98].&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Active opportunistic infection or HIV-related malignancy [HIV-related malignancy&#xD;
             deleted AS PER AMENDMENT 11/25/98].&#xD;
&#xD;
          -  Peripheral neuropathy of grade 2 or higher by Division of AIDS toxicity criteria.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Other investigational HIV-drugs.&#xD;
&#xD;
          -  Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids,&#xD;
             hematopoietins, interleukin-2, interferon, or pentoxifylline.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        History of serious hypersensitivity to tetanus toxoid or any of the vaccine components.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Previous immunization with pneumococcal polysaccharide vaccine [or, AS PER AMENDMENT&#xD;
             11/25/98, keyhole limpet hemocyanin vaccine].&#xD;
&#xD;
          -  Tetanus toxoid booster within 5 years [deleted AS PER AMENDMENT 11/25/98].&#xD;
&#xD;
          -  Other investigational HIV-drugs within 6 weeks of enrollment.&#xD;
&#xD;
          -  Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids,&#xD;
             hematopoietins, interleukin-2, interferon, or pentoxifylline within 6 weeks of&#xD;
             enrollment.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Active drug or alcohol abuse.&#xD;
&#xD;
        Required:&#xD;
&#xD;
        Effective combination antiretroviral therapy including two nucleoside analog agents (ZDV,&#xD;
        3TC, ddI, ddC, or d4T) and nelfinavir or indinavir, for at least one month prior to study&#xD;
        entry. [AS PER AMENDMENT 11/25/98:&#xD;
&#xD;
          -  On stable, effective, highly-active antiretroviral therapy with combinations of any&#xD;
             FDA-approved anti-HIV drugs for at least 3 months prior to entry.]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Lymphocyte Transformation</keyword>
  <keyword>Immunity, Cellular</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Immunologic Memory</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Tetanus Toxoid</keyword>
  <keyword>Pneumococcal Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

